Corcept Therapeutics (CORT) Misses Q4 EPS by 5c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.47 +3.58%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.05 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $202.12 million versus the consensus estimate of $249.52 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.9-1 billion, versus the consensus of $0.96 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
- Nomura/Instinet Downgrades Indraprastha Gas Ltd. (IGL:IN) to Neutral
- Citi Upgrades Zhejiang Dahua Technology (002236:CH) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
